論文

国際誌
2021年1月27日

Distinct epigenetic signatures between adult-onset and late-onset depression.

Scientific reports
  • Hirotaka Yamagata
  • Hiroyuki Ogihara
  • Koji Matsuo
  • Shusaku Uchida
  • Ayumi Kobayashi
  • Tomoe Seki
  • Masaaki Kobayashi
  • Kenichiro Harada
  • Chong Chen
  • Shigeo Miyata
  • Masato Fukuda
  • Masahiko Mikuni
  • Yoshihiko Hamamoto
  • Yoshifumi Watanabe
  • Shin Nakagawa
  • 全て表示

11
1
開始ページ
2296
終了ページ
2296
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1038/s41598-021-81758-8

The heterogeneity of major depressive disorder (MDD) is attributed to the fact that diagnostic criteria (e.g., DSM-5) are only based on clinical symptoms. The discovery of blood biomarkers has the potential to change the diagnosis of MDD. The purpose of this study was to identify blood biomarkers of DNA methylation by strategically subtyping patients with MDD by onset age. We analyzed genome-wide DNA methylation of patients with adult-onset depression (AOD; age ≥ 50 years, age at depression onset < 50 years; N = 10) and late-onset depression (LOD; age ≥ 50 years, age at depression onset ≥ 50 years; N = 25) in comparison to that of 30 healthy subjects. The methylation profile of the AOD group was not only different from that of the LOD group but also more homogenous. Six identified methylation CpG sites were validated by pyrosequencing and amplicon bisulfite sequencing as potential markers for AOD in a second set of independent patients with AOD and healthy control subjects (N = 11). The combination of three specific methylation markers achieved the highest accuracy (sensitivity, 64%; specificity, 91%; accuracy, 77%). Taken together, our findings suggest that DNA methylation markers are more suitable for AOD than for LOD patients.

リンク情報
DOI
https://doi.org/10.1038/s41598-021-81758-8
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33504850
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840753
ID情報
  • DOI : 10.1038/s41598-021-81758-8
  • PubMed ID : 33504850
  • PubMed Central 記事ID : PMC7840753

エクスポート
BibTeX RIS